ESO Lymphoma Course

 

Videos
18:40

ESO Lymphoma Course

Chemo-free Therapy for Follicular Lymphoma - Rituximab as Single Agent, Rituximab + Lenalidomide & Other Combinations

FEATURING Emanuele Zucca
  • 153 views
  • August 19, 2019
39:10

ESO Lymphoma Course

Hodgkin Lymphoma - Kairos vs. Chronos Principle & New Active Agents (Antibody-Drug Conjugates and Checkpoint Antibodies)

FEATURING Peter Johnson
  • 66 views
  • August 19, 2019
14:43

ESO Lymphoma Course

The Mutational Landscape of CLL: Diagnosis, Survival, and Watch and Wait

FEATURING Davide Rossi
  • 323 views
  • August 19, 2019
  • 2
19:04

ESO Lymphoma Course

The Mutational Landscape of CLL: 1st line, Fixed Duration Treatment, TP53 Status, 2nd Line Setting and MRD

FEATURING Davide Rossi
  • 169 views
  • August 19, 2019
  • 1
22:43

ESO Lymphoma Course

R-CHOP Therapy for 61 y/o Male with Stage IIIB bulky DLBCL & Avoiding Radiotherapy if PET-Negative

FEATURING Alden Moccia
  • 6 views
  • August 30, 2019
23:01

ESO Lymphoma Course

Treatment of 58 y/o Male with Stage IV B Marginal Zone lLymphoma : Transformation of Disease into DLBCL

FEATURING Alden Moccia
  • 37 views
  • August 30, 2019
31:37

ESO Lymphoma Course

Efficacy and Safety of Anti-CD19 CAR T-cell Therapy in B-cell Lymphoma, Update on ZUMA - 1 Trial & Strategies for Improving Efficacy of CAR T Therapy

FEATURING Sattva Neelapu
  • 115 views
  • September 3, 2019
  • 1
26:51

ESO Lymphoma Course

Management of Mantle Cell Lymphoma: Prognostic Factors, Younger vs. Older Treatment Algorithms & Efficacy of R-BAC After Progression on BTKi Therapy

FEATURING Simon Rule
  • 67 views
  • September 3, 2019
31:53

ESO Lymphoma Course

Update on Primary and Secondary CNS Lymphoma: Diagnosis, Treatment Options, Review of Top Trials and Salvage Therapy

FEATURING Tracy Batchelor
  • 54 views
  • September 3, 2019
18:27

ESO Lymphoma Course

Update on Waldenstrom's Macroglobulinemia: Somatic Mutation in MYD88 and CXCR4, Review of Available Treatment Options & Ongoing Trials

FEATURING Bernhard Gerber
  • 132 views
  • September 3, 2019
22:17

ESO Lymphoma Course

First Line DLBCL: How Many Cycles of RCHOP? Improving Outcomes of CHOP: R-CHOP vs. R-ACVBP vs. DA-EPOCH-R, R-CODOX-M vs. R-IVAC

FEATURING Andrew Davies
  • 235 views
  • September 3, 2019
  • 1
18:20

ESO Lymphoma Course

Should We Add Other Agents Like Obinutuzumab, Lenalidomide, Bortezomib or Ibrutinib to R-CHOP? How to Decide Which DLBCL Patients Should Receive CNS Prophylaxis?

FEATURING Andrew Davies
  • 46 views
  • September 3, 2019
09:10

ESO Lymphoma Course

Evolution of Cancer Therapies: Molecular Selection of Patients, Histology Agnostic Therapies & Costs and Success Rates in Oncology Drug Development

FEATURING Anastasios Stathis
  • 10 views
  • September 4, 2019
09:22

ESO Lymphoma Course

Main Phases of Clinical Drug Development, New Trials Designs (Umbrella Trial vs. Basket Trial) & Seamless Oncology Drug Development

FEATURING Anastasios Stathis
  • 8 views
  • September 4, 2019
07:54

ESO Lymphoma Course

Current and Future Drug Development in DLBCL: Review of Methodology, Failure History & New Trial Design

FEATURING Anastasios Stathis
  • 21 views
  • September 4, 2019
21:39

ESO Lymphoma Course

Case of 58 y/o Male with IgM Multiple Myeloma and Amyloidosis: Disease Progression and Discussion on Best Treatment Options

FEATURING Bernhard Gerber
  • 60 views
  • September 5, 2019
11:39

ESO Lymphoma Course

Treatment of 57 y/o Male with B-Lymphoblastic Lymphoma

FEATURING Bernhard Gerber
  • 17 views
  • September 5, 2019
32:00

ESO Lymphoma Course

The AML Paradigm: From 3+7 for Everybody to Genetic-Driven Personalized Treatment

FEATURING Martin Fey
  • 223 views
  • September 5, 2019
  • 2
33:55

ESO Lymphoma Course

Pathogenesis of Mature B-Cell Lymphomas: Germinal Center‐derived Lymphomas, Somatic Mutations, MALT1 Inhibitor, Metabolic Adaptation & SIRT3 Metabolic Target

FEATURING Ari Melnick
  • 78 views
  • September 12, 2019
22:37

ESO Lymphoma Course

Common "Epigenetic" Somatic Mutations in Lymphoma: CREBBP, EP300, HDAC3, TET2, KMT2D, EZH2

FEATURING Ari Melnick
  • 39 views
  • September 12, 2019
16:32

ESO Lymphoma Course

Biology of T-cell Lymphoma: PTCL Molecular Characterisation & Entities, Follicular Helper, Mutations and Epigenetic Modifiers

FEATURING Laurence de Leval
  • 29 views
  • September 12, 2019
12:07

ESO Lymphoma Course

Biology of Anaplastic Large Cell Lymphomas (ALK+ and ALK-) & Breast Implant‐associated ALCL

FEATURING Laurence de Leval
  • 22 views
  • September 12, 2019
17:15

ESO Lymphoma Course

Biology of Extranodal NK/T-cell Lymphoma: Mutations and Pathways, EATL vs MEITL, ATLL Genomic Profiling & Genetic Profiling of PTCLS-NOS

FEATURING Laurence de Leval
  • 21 views
  • September 12, 2019
  • 1
28:05

ESO Lymphoma Course

Biology of Hodgkin Lymphoma: IgV Gene Rearrangements, Factors Contributing to Lost B Cell Identity of HRS Cells & Genetic Lesions in HRS Cells

FEATURING Ralf Küppers
  • 16 views
  • September 12, 2019
22:48

ESO Lymphoma Course

Biology of Hodgkin Lymphoma: Relationship Between Hodgkin and Reed-Sternberg Cells & Gene Expression Profiling Analysis of CD30+ B vs. HRS Cells

FEATURING Ralf Küppers
  • 15 views
  • September 12, 2019